IDSA/SHEA Clostridium difficile Infection - Merck Flipbook

Clostridium Difficile - Treatment in Adults

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/943539

Contents of this Issue

Navigation

Page 4 of 9

➤ Treat a first recurrence with a standard 10-day course of vancomycin rather than a second course of metronidazole if metronidazole was used for the primary episode (W-L). ➤ Antibiotic treatment options for patients with more than one recurrence include (W-L): • oral vancomycin therapy using a tapered and pulsed regimen, • a standard course of oral vancomycin followed by rifaximin, or • fidaxomicin. ➤ Fecal microbiota transplantation (FMT) is recommended for patients with multiple recurrences who have failed appropriate antibiotic treatments (S-M). ➤ There are insufficient data at this time to recommend extending the length of anti-C. difficile treatment beyond the recommended treatment course or restarting an anti-C. difficile agent empirically for patients who require continued antibiotic therapy directed against the underlying infection or who require retreatment with antibiotics shortly after completion of treatment, respectively (NR). Important Safety Information DIFICID is contraindicated in pa ents with hypersensi vity to fidaxomicin. DIFICID should not be used for systemic infec ons. Acute hypersensi vity reac ons, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin. If a severe hypersensi vity reac on occurs, DIFICID should be discon nued and appropriate therapy should be ins tuted.

Articles in this issue

view archives of IDSA/SHEA Clostridium difficile Infection - Merck Flipbook - Clostridium Difficile - Treatment in Adults